At a glance

Stallergenes Greer is a fully integrated global biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory, food, and venom allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services. AIT is an allergy treatment designed to treat the underlying cause of the disease by rebalancing the immune system. Ait can alter the natural course of allergies and is a therapeutic class capable of modifying disease progression.

Stallergenes Greer boasts a broad global footprint and extensive allergen and
finished AIT product manufacturing capabilities.

 

Four pillars form the framework of our corporate responsibility programme, Care Beyond Allergy. They emphasise our responsibility both as a company and as an employer and focus on areas in which we can make a difference: society, environment, social and governance.

The foundation’s mission is “to create healthier futures for all” by: focusing on scientific research to bolster innovation and precision medicine; supporting academic initiatives to develop future generations of allergy healthcare professionals; and engaging in climate action and environmental protection to progress the prevention and treatment of allergies.

What’s new